Member Info for CTSFO

An overview of the state of play in development of polymeric heart valves. A bit about the competition out there.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10034107/

That dilution must have hurt. Been burnt by Avacta doing something similar.

Hope a post from a FNB / FNI is okay? 62,000,000 shares in circulation, 60% of these in ‘sticky hands’. This broker note suggests an mcap of £120,000,000. It’s worth reading, especially the analysis of the safety concerns re synthetic heart valves.

https://www.equitydevelopment.co.uk/hubfs/RUA%20Life%20Sciences%20plc%20-%2026%20July%202023%20note.pdf

Touk, it’s not a dilution that’s taking place. That would mean the the mass of drug has remained the same and blood volume has increased.

So the Pt1/2 of AVA6000 is going to be caused by its breakdown at the TME (good), breakdown throughout at non cancer sites (bad), and clearance of AVA6000 by kidneys or liver (good as long as no toxicity). All drugs have to be removed from the body - one way or another. So if the t1/2 is mainly because of FAP breakdown of AVA6000 at the TME, this is actually a good thing.

Earl - thanks for the heads-up on GST.

Those late trades were a kick in the nuts tbh.

Swazers, hi, what do you think the future holds?

I’m officially 🤡 of the day. You’re all absolutely right, it is main market. Sorry!

A criticism of AIM, not GST.

I hope the market can, for once, allow some good news to add sustained value to a company. Sick of SPs falling back to no gain after supportive RNSs. Ignore the spike, but at least a sustained > 10% rise would be reasonable.

Can I ask for some help please? Are there any Brokers’ Notes about GST out there? Damned if I can find one! I’m quite happy for them to DYOR for me…

I’ve been very very badly burned by a fintech promising the world. Every RNS / comms deadline missed.

GST quietly getting the ducks lined up, and cats hearded together, ready for a coordinated launch coinciding with a central gov announcement re crypto works for me.

I’m very new to GST and this BB.

OH THANK GOD… sensible discussion, and anyone suggesting caution with expectations isn’t shot down in flames as a fudster.

🙏

GLA.

Once an entity has bought 30% of the shares in a company they must declare if they are intending to takeover that company or not. If not, they are not able to launch a takeover bid for a defined period. Possibly 6 months?

All set out here:

https://www.thetakeoverpanel.org.uk/

Nothing to stop secret talks being held, then a recommendation, or not, to accept the offer.

Wyndrum: that’s an excellent, thoughtful, post.

NYsize: you’re right, no point in moaning. It’s just so frustrating at present. But it doesn’t help or change anything.

I’m putting the pitchfork back in the shed.

GLA.

NYsize makes a very important comment about the state of the market. AIM is in terminal decline. I hope the link works. We need a CEO who can manage this very turbulent financial environment, whilst a CSO looks after the science - great post BV.

I hear what NYsize says about turning on AS. But likewise business is about evaluation and re-evaluation. Maybe AS is the best CEO? But it’s also fair to question that as the company evolves, and market’s significantly change, is there someone better suited to lead Avacta forward?

https://www.cityam.com/is-the-london-stock-exchanges-aim-in-terminal-decline/

Simple question. Is AS the best CEO Avacta could have. Avoiding ad hominem insults against him, he’s doing the best he can with a pure science background. He’s a scientist. Shouldn’t there be a Pharma trained businessperson running the company?

THIS:

“ It’s very rare (unprecedented as far as I’m aware) that a company can be so specific in the recruitment of patients in a phase 1 study. There are massive forces in play behind the decisions that have been made (FDA/BP) and the two weekly has the feel of a phase 2/3 efficacy study.”

🔨💅👦

I saw Wyndrum’s original post. 🙏👌👏👏👏. I don’t think AS is going to have an easy time of it. Not sure how he’s going to enjoy being reminded he doesn’t own the company, and he is answerable to shareholders. I’m guessing not many ‘science’ questions are heading his way.

Bring popcorn 🍿.

“ An FDA encouraged t/o before the end of the year....in my opinion.”

WTF? WTAF?? WTAFFOAFFB???

The FDA is a safety & regulatory US Government Agency. It doesn’t advise companies, or anything else, on business development matters. That would be seen as gross market manipulation. It simply cannot do this. It has no means, ability, or authority to interfere like that.

“ Trinity Delta view: The proprietary pre|CISION platform is key to Avacta's investment case, hence updated data that continue to support key hypotheses for AVA6000 are reassuring. Future efficacy data from studies planned to start in H224 will be key, and could also help to more broadly validate pre|CISION. The recent £31.1m fundraise (March 2024 Lighthouse), which provides a cash runway of c 24 months ie into early 2026, will be used to advance the therapeutics pipeline, in particular AVA6000, and should cover a number of value inflection points in AVA6000's development. Our valuation and forecasts are currently suspended; our last published valuation was £672m (equivalent to 237p/share).”